No Detail Found!

Clinical Signi cance of Decreased GPX1 Expression in Patients with Acute Myeloid Leukaemia (Non-M3)

Author(s)
Xiaolin Liang Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Yibin Yao Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Huiqun Li Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Jie Wei Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Chengyao Wan Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Zhenfang Liu Department of Hematology, The First Affiliated Hospital of Guangxi Medical University,Nanning, Guangxi,China
Abstract
Objective: To determine the expression levels oGfPX1, SOCS5 and IL7 and their clinical signi cance in patients with acute myeloid leukaemia (AML). Study Design: A case-control study. Place and Duration of Study:Department of Hematology, The First A liated Hospital of Guangxi Medical University, Nanning, Guangxi, China, from January 2013 to November 2020. Methodology: Based on the bioinformatics analysis, the expression levels of GPX1, SOCS5 and IL7 in the bone marrow of 64 AML patients (non-M3) and 32 healthy individuals were evaluated by real-time PCR. Correlation betweenGPX1 expression and the clinical characteristics, response to induced chemotherapy, and survival time of AML patients were analysed as the outcome measure. Results: GPX1 was signi cantly downregulated in AML patients, which helped in distinguishing AML patients from normal controls. The area under the curve (AUC) of the receiver operator characteristic (ROC) was 0.741 (p <0.001). Additionally, GPX1 expression was correlated with gender (r = -0.250, p = 0.045), FAB classi cation (r = -0.332p, = 0.004), and chemotherapy response (r = 0.366, p = 0.003). AML patients with high GPX1 expression levels had a lower rate of remission (p = 0.021) and poor long-term survival (p = 0.036) than those with low GPX1 expression levels. Conclusion: Low GPX1 expression in AML patients may be closely associated with the pathogenesis and chemoresistance of AML.
Publication Details
Page(s) 941-946
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 8, Year: 2021

Request the full text from PASTIC

Keywords
gene expression, Clinical outcome, Acute myeloid leukaemia, GPX1
0

Citations

0

Downloads

74

Views